Patents Represented by Attorney, Agent or Law Firm Kenneth J. Dow
-
Patent number: 8338171Abstract: Polynucleotide sequences encoding a baboon homolog of human CD147 and polypeptides obtainable form the polynucleotides and uses are disclosed.Type: GrantFiled: August 12, 2010Date of Patent: December 25, 2012Assignee: Centocor Ortho Biotech Inc.Inventors: Bethany Swencki-Underwood, Michael Naso
-
Patent number: 8293882Abstract: Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.Type: GrantFiled: March 27, 2009Date of Patent: October 23, 2012Assignee: Centocor, Inc.Inventors: G. Mark Anderson, Bernard Scallon, Michael Naso, Ann Cai, Cam Ngo
-
Patent number: 8278415Abstract: Polypeptides comprising EGFR extracellular domains I-III capable of forming dimeric EGF-binding proteins are provided. The dimeric construct of the invention is useful in applications where high affinity EGF binding is desired and can be used to select agents capable of binding to native EGFR in the presence of EGF.Type: GrantFiled: December 20, 2007Date of Patent: October 2, 2012Assignee: Centocor, Inc.Inventors: Wang Bryan, Frank Shi, Juliane Mills
-
Patent number: 8138315Abstract: An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha V subunit including ?v?1, ?v?3 ?v?5, ?v?6, or ?v?8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab? fragment, a scFv, or the like. Binding of the immunoliposome to ?v-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent.Type: GrantFiled: May 11, 2011Date of Patent: March 20, 2012Assignee: Centocor Ortho Biotech Inc.Inventors: Joshua Goldstein, Allen Magill, Deepak Saini, Linda A. Snyder, Raymond Sweet, Steve P. Weng
-
Patent number: 8071333Abstract: The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: April 21, 2009Date of Patent: December 6, 2011Assignee: Centocor, Inc.Inventors: Jill Giles-Komar, Linda Snyder, Mohit Trikha, Marian T. Nakada
-
Patent number: 8071729Abstract: The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: October 31, 2007Date of Patent: December 6, 2011Assignee: Centocor, Inc.Inventors: Jill Giles-Komar, Linda Snyder, Mohit Trikha, Marian T. Nakada
-
Patent number: 7955597Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: July 23, 2009Date of Patent: June 7, 2011Assignee: Centocor, Inc.Inventors: Jill Giles-Komar, David Knight, David Peritt, Mohit Trikha
-
Patent number: 7833786Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: October 30, 2007Date of Patent: November 16, 2010Assignee: Centocor, Inc.Inventors: Jill Giles-Komar, David Knight, David Peritt, Mohit Trikha
-
Patent number: 7790405Abstract: The invention relates to a method of directing selection of biological therapeutic molecules to specific functional domains of the target biologic molecule. Selection is directed by the use of closely related molecules, where one is a decoy and the other contains the targeted domain or epitope. The invention is based on the use of physical data, which may be combined with derived data, to ascertain that the decoy and the target differ only in the specific functional domain or epitope where the binding will be directed.Type: GrantFiled: April 22, 2005Date of Patent: September 7, 2010Assignee: Centocor, Inc.Inventors: Karyn O'Neil, Raymond Sweet, George Heavner
-
Patent number: 7777018Abstract: The present invention provides CDR-grated antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also provides methods of making the CFR-grafted antibodies and pharmaceutical compositions for the attenuation or prevention of coagulation.Type: GrantFiled: October 29, 2007Date of Patent: August 17, 2010Assignee: Centocor, Inc.Inventors: Linda K. Joliffe, Robert A. Zivin, Virginia L. Pulito
-
Patent number: 7612182Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: August 1, 2007Date of Patent: November 3, 2009Assignee: Centocor, Inc.Inventors: Jill Giles-Komar, David Knight, David Peritt, Mohit Trikha
-
Patent number: 7605235Abstract: Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.Type: GrantFiled: December 13, 2004Date of Patent: October 20, 2009Assignee: Centocor, Inc.Inventors: G. Mark Anderson, Bernard Scallon, Michael Naso, Ann Cai, Cam Ngo
-
Patent number: 7550142Abstract: The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: November 13, 2006Date of Patent: June 23, 2009Assignee: Centocor, Inc.Inventors: Jill Giles-Komar, Linda Snyder, Mohit Trikha, Marian T. Nakada
-
Patent number: 7547767Abstract: The present invention provides novel proteins and peptides from the receptor binding region of human Growth Arrest Specific Gene 6 (Gas6) and antibodies, including specified portions or variants, specific for at least one such Gas6 peptide or fragment thereof. The aforesaid peptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and/or CDR-grafted anti-Gas6 antibodies. The invention also provides for the nucleic acids encoding such peptides and anti-Gas6 antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, including therapeutic formulations, administration and devices. Fifteen novel peptide sequences from the Gas6 G domain that are implicated in Gas6 interactions with its receptors are identified, isolated, and synthesized so as to allow generation of anti-Gas6 antibodies. The peptide sequences include three ESTs that encompass regions predicted to contribute to receptor binding or that can raise anti-Gas6 antibodies.Type: GrantFiled: November 21, 2006Date of Patent: June 16, 2009Assignee: Centocor Ortho Biotech Inc.Inventors: Jing Yang, George Heavner, Robert Jordan, Jill Giles-Komar, Ray Sweet
-
Patent number: 7544790Abstract: The present invention provides CDR-grated antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also provides methods of making the CFR-grafted antibodies and pharmaceutical compositions for the attenuation or prevention of coagulation.Type: GrantFiled: November 1, 2006Date of Patent: June 9, 2009Assignee: Centocor, Inc.Inventors: Linda K. Joliffe, Robert A. Zivin, Virginia L. Pulito
-
Patent number: 7521206Abstract: The present invention relates to at least one novel anti-TNF antibodies, including isolated nucleic acids that encode at least one anti-TNF antibody, TNF, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: July 13, 2005Date of Patent: April 21, 2009Assignee: Centocor, Inc.Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
-
Patent number: 7514539Abstract: A tissue factor antibody which binds to non-human tissue factor and is useful as a surrogate in preclinical testing where the human therapeutic tissue factor candidate antibody does not interact with the homolog target protein in a manner that would provide meaningful information about treatment efficacy or safety.Type: GrantFiled: April 22, 2005Date of Patent: April 7, 2009Assignee: Centocor, Inc.Inventors: Karyn O'Neil, Raymond Sweet
-
Patent number: 7427471Abstract: The invention relates to the field of antibodies, and particularly to modified antibodies, methods of preparing modified antibodies and uses thereof. More particularly, the invention relates to the preparation of more active IgG antibodies by the addition of an extra immunoglobulin domain to the constant region.Type: GrantFiled: June 5, 2003Date of Patent: September 23, 2008Assignee: Centocor, Inc.Inventors: Bernard J. Scallon, Ann Cai, Michael Naso
-
Patent number: 7365154Abstract: The invention concerns antagonists of alphav-containing integrins which have therapeutic activity in oncology applications and methods for selecting such antagonists using a peptide which competes for alphaV-integrin binding with a known monoclonal antibody having demonstrated anti-tumor activity. The claimed peptide represents a conformational epitope or mimotope present on the ligand to which the therapeutic antibodies selectively bind.Type: GrantFiled: June 22, 2004Date of Patent: April 29, 2008Assignee: Centocor, Inc.Inventors: David Shealy, Sam Wu, Yan Chen, Audrey Baker
-
Patent number: 7291721Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: October 26, 2002Date of Patent: November 6, 2007Assignee: Centocor, Inc.Inventors: Jill Giles-Komar, David Knight, David Peritt, Mohit Trikha